Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Jun 7, 2023
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down Jun 1, 2023
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market May 22, 2023
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer May 11, 2023
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications May 8, 2023
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit Apr 27, 2023
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694 Apr 13, 2023
Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down Mar 30, 2023
